Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
Owen DH, Benner B, Wei L, Sukrithan V, Goyal A, Zhou Y, Pilcher C, Suffren SA, Christenson G, Curtis N, Jukich M, Schwarz E, Savardekar H, Norman R, Ferguson S, Kleiber B, Wesolowski R, Carson WE, Otterson GA, Verschraegen CF, Shah MH, Konda B. Owen DH, et al. Among authors: sukrithan v. Clin Cancer Res. 2023 Feb 16;29(4):731-741. doi: 10.1158/1078-0432.CCR-22-1552. Clin Cancer Res. 2023. PMID: 36255391 Free PMC article.
Emerging drugs for the treatment of adrenocortical carcinoma.
Sukrithan V, Husain M, Kirschner L, Shah MH, Konda B. Sukrithan V, et al. Expert Opin Emerg Drugs. 2021 Jun;26(2):165-178. doi: 10.1080/14728214.2021.1920922. Epub 2021 May 3. Expert Opin Emerg Drugs. 2021. PMID: 33896321 Review.
Kinase inhibitors in thyroid cancers.
Sukrithan V, Jain P, Shah MH, Konda B. Sukrithan V, et al. Endocr Oncol. 2023 Jan 13;3(1):e220062. doi: 10.1530/EO-22-0062. eCollection 2023 Jan 1. Endocr Oncol. 2023. PMID: 37434642 Free PMC article. Review.
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors.
Abuzakhm SM, Sukrithan V, Fruth B, Qin R, Strosberg J, Hobday TJ, Semrad T, Reidy-Lagunes D, Kindler HL, Kim GP, Knox JJ, Kaubisch A, Villalona-Calero M, Chen H, Erlichman C, Shah MH. Abuzakhm SM, et al. Among authors: sukrithan v. Endocr Relat Cancer. 2023 Sep 13;30(11):e220301. doi: 10.1530/ERC-22-0301. Print 2023 Nov 1. Endocr Relat Cancer. 2023. PMID: 37702588 Free PMC article. Clinical Trial.
Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.
Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes AM, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM, Mukherjee S, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG, Verma A. Bhagat TD, et al. Among authors: sukrithan v. Cancer Res. 2017 Sep 15;77(18):4846-4857. doi: 10.1158/0008-5472.CAN-17-0282. Epub 2017 Jul 6. Cancer Res. 2017. PMID: 28684528 Free PMC article.
Emerging drugs for EGFR-mutated non-small cell lung cancer.
Sukrithan V, Deng L, Barbaro A, Cheng H. Sukrithan V, et al. Expert Opin Emerg Drugs. 2019 Mar;24(1):5-16. doi: 10.1080/14728214.2018.1558203. Epub 2018 Dec 20. Expert Opin Emerg Drugs. 2019. PMID: 30570396 Review.
22 results